FDA expands Pfizer vaccine’s booster authorization to include 16- and 17-year-olds; CDC recommends
The Food and Drug Administration today announced the widely anticipated expansion of Pfizer’s COVID-19 vaccine emergency use authorization to allow booster doses for 16- and 17-year-olds. The FDA said boosters for this age group should be administered at least six months following the completion of an initial two-dose regiment. Following FDA’s decision, the Centers for Disease Control and Prevention formally recommended boosters for this age group.
“We know that COVID-19 vaccines are safe and effective, and I strongly encourage adolescents ages 16 and 17 to get their booster if they are at least 6 months post their initial Pfizer vaccination series,” said CDC Director Rochelle Walensky, M.D.
Related News Articles
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…